OBJECTIVES: Cardioplegic arrest using a polarizing solution has been shown to have beneficial advantages for cardioprotection compared with depolarizing (potassium-based) arrest; most studies, however, have looked at normothermic ischaemia with short infusion intervals (every 10-15 min). This study examines the protective efficacy of an esmolol-based cardioplegia during hypothermic arrest, together with a prolonged infusion interval (30 min) for increased clinical feasibility.
INTRODUCTION
Myocardial protection during cardiac surgery, predominantly with potassium-based cardioplegia [1] , enabled significant improvement in postoperative mortality and morbidity. However, the depolarized arrest induced by hyperkalaemia exerts some detrimental effects on the ischaemic myocardium, including ionic imbalance, maintained energy utilization and continuing ischaemia-reperfusion injury [1] . There is increasing interest in alternative concepts to induce arrest, with agents such as sodium channel blockers [2, 3] , which have shown improved myocardial protection but have toxic effects at high doses [4] . Our studies [5, 6] have previously demonstrated the potential of high-dose (1 mmol/l) esmolol as a cardioplegic arresting agent, where it was shown to provide at least equivalent protection to St Thomas' Hospital cardioplegia (STH2) and to be effective as a bloodbased solution [7] . Esmolol is an ultra-short-acting cardioselective b-blocker with a half-life of around 9 min [8] ; it has a phenoxypropanolamine nucleus, a molecular weight of 332 kDa, an empirical formula of C 16 H 26 N0 4 and an ester linkage in the formulation that is responsible for its cardioselectivity and rapid deactivation by hydrolysis of tissue and blood esterases. The short half-life of esmolol makes this b-blocker more suitable for use in the acute setting (such as cardiac surgery) than conventional b-blockers with prolonged negative inotropic and chronotropic properties. We [9] have also characterized the negative inotropic effects of high-dose esmolol and shown that its mechanism of action is to block the activity of both L-type calcium channels and fast sodium channels.
Esmolol was previously shown to exert protective effects during cardiac surgery, either as an additive during cardiopulmonary bypass [10] or as a substitute for potassium-based blood cardioplegia [11] . These studies used continuous infusion of esmolol (to achieve systemic doses of approximately 10-30 mmol/l); in our studies, esmolol (1 mmol/l) was infused intermittently throughout global ischaemia at 10-min intervals. This infusion interval would be impractical surgically (where infusion intervals are usually around 20-30 min); however, studies into hypothermic degradation of esmolol [12, 13] suggest that hypothermia extends the effective half-life without any adverse effects (including weaning from CPB), and this may translate into the ability to extend the infusion interval duration when esmolol is used in a cardioplegic solution. We speculated that any persistent b-blockade during hypothermia would be abolished after cessation and rewarming and that any protective effect of esmolol may be enhanced by hypothermia. In this study, we investigated whether the efficacy of esmolol cardioplegia was influenced by mild (tepid) hypothermia (32 C) when compared with STH2 and also examined the protective efficacy of esmolol cardioplegia at various temperatures appropriate for cardiac surgery.
MATERIALS AND METHODS

Animals
Adult male Wistar rats (220-300 g of body weight) were used (Bantin and Kingman, Hull, UK). All animals received humane care in accordance with the Guidance on the Operation of the Animals (Scientific Procedure) Act of 1986 published by Her Majesty's Stationary Office, London, UK.
Heart isolation and perfusion
Rat hearts were perfused in the Langendorff mode as described previously [14] . Briefly, hearts were rapidly excised from anaesthetized (pentobarbitone sodium, 60 mg/kg intraperitoneally) and anticoagulated (heparin, 1000 IU/kg intravenously) rats, cannulated by the aorta (within 30 s) and perfused in the Langendorff mode at constant pressure (75 mmHg) and temperature (37 C) with Krebs-Henseleit bicarbonate buffer (KHB). An ultrathin intraventricular balloon, constructed from cling film (Saran Wrap; S. C. Johnson, Racine, WI, USA) over the tip of a 20-gauge cannula, was introduced into the left ventricle. The balloon was attached to a pressure transducer, and the calibrated output was recorded on a computer (Apple Computer Inc., Cupertino, CA, USA) using the PowerLab system (AD Instruments Ltd, Chalgrove, Oxfordshire, UK). The intraventricular balloon was gradually inflated with water to give a stable left ventricular enddiastolic pressure (LVEDP) of 3.0-8.0 mmHg, and this isovolumic state was maintained throughout the protocol.
Hearts were subjected to 20-min aerobic equilibration perfusion; a unipolar electrocardiogram was continuously recorded throughout to measure the heart rate (HR). Baseline readings of left ventricular systolic pressure (mmHg), LVEDP (mmHg), HR (beats/min) and coronary flow (CF) rate (ml/min) were taken at the 20-min equilibration period. Left ventricular developed pressure (LVDP) was calculated as left ventricular systolic pressure minus LVEDP. CF rate was measured by timed collections of coronary effluent. The development of contracture during ischaemia was recorded.
Exclusion criteria
Hearts not satisfying preassigned exclusion criteria at baseline were excluded. Acceptable values for LVDP, HR and CF rate were >100 mmHg, >220 beats/min and 8-16 ml/min, respectively. .0 was prepared daily. The pH was adjusted to 7.8 at 37 C and filtered through a 5-lm cellulose nitrate filter before use. These solutions were delivered at 32 C and at constant pressure (45 mmHg) for 3-min infusion durations (Fig. 1) .
Perfusion protocols
Each heart was perfused with KHB from a temperature-regulated reservoir (37 C) at constant perfusion pressure equivalent to 75 mmHg before and after global ischaemia. During ischaemia, hearts were kept at the specified temperature with a temperature-controlled, water-jacketed heart chamber.
Study 1: efficacy of tepid (32 C) hypothermia on myocardial protection with esmolol cardioplegia or St Thomas' Hospital cardioplegia A: 60-min ischaemia. Hearts (n = 6 per group) were randomly assigned to 1 of the 5 groups ( Fig. 1 ): (i) 60-min global ischaemia alone (GI), (ii) single-dose STH2 before 60-min global ischaemia (SS), (iii) single-dose EC infused for 3 min before 60-min global ischaemia (SE), (iv) multidose STH2 infused for 3 min before and every 30 min during 60-min global ischaemia (MS) and (v) multidose EC infused for 3 min before and every 30 min during 60-min global ischaemia (ME). All hearts were aerobically reperfused for 60 min, and recovery of myocardial function was measured.
B + C: 90-min or 120-min ischaemia. Global ischaemia was prolonged to 90 or 120 min; hearts (n = 6 per group) were randomly assigned to 1 of the 3 groups ( Fig. 1 ): (vi/ix) single-dose STH2 before 90-min or 120-min global ischaemia (SS), (vii/x) multidose STH2 infused for 3 min before and every 30 min during 90-min or 120-min global ischaemia (MS) and (viii/xi) multidose EC infused for 3 min before and every 30 min during 90-min or 120-min global ischaemia (ME).
Study 2: efficacy of esmolol cardioplegia on myocardial protection at various temperatures
Hearts (n = 6 per group) were randomly assigned to 1 of the 8 groups (Fig. 1) ; all hearts were subjected to multidose infusions of KHB or EC every 30 min during 120 min of global ischaemia at 20 C, 28 C, 32 C or 37 C throughout ischaemia. In all protocols, hearts were aerobically reperfused for 60 min, and recovery of myocardial function was measured. All hearts were weighed after 60 min reperfusion. In Study 1B, Study 1C and Study 2, myocardial injury (creatine kinase leakage) was also measured following reperfusion. In Study 2, myocardial viability [triphenyl tetrazolium chloride (TTC) staining] was also measured after reperfusion.
Expression of results
Contractile function. Postischaemic recovery of LVDP, HR
and CF rate was expressed as percentage of baseline value (20-min equilibration); LVEDP and contracture were expressed in mmHg. Ischaemic contracture was characterized by a rise in LVEDP during global ischaemia and is associated with an adenosine triphosphate depletion and calcium influx [15, 16] .
Creatine kinase leakage. Total creatine kinase (CK) leakage (IU/g heart wet weight) was assessed using a commercially available kit (CK NAC-activated kit; Randox Laboratories Ltd, UK) by spectrophotometric analysis of enzyme activity in the coronary effluent collected at each infusion of cardioplegic solution (except the first infusion) and during the reperfusion periods.
Triphenyl tetrazolium chloride staining. Hearts were frozen after 60 min of reperfusion and stored for later analysis. TTC staining was measured using a modification of the method by Ferrera et al. [17] ; hearts were placed in a conical tube, finely minced in 5 ml of 4 C phosphate-buffered solution containing TTC (1 mmol/l) and incubated at 37 C for 90 min. TTC solution was removed, and 5 ml of dimethyl sulfoxide was added to extract the stain from the heart. The samples were left overnight and then centrifuged to separate the supernatant from heart fragments. The absorbance of the supernatant was measured at 550 nm, and the results were expressed as arbitrary units per gram of wet heart weight.
Statistics
Statistical analysis was performed with GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA) on an Apple Macintosh computer (Apple Computer Inc.). All data were reported as mean ± standard error of the mean. Comparisons between groups were assessed for significance by 2-way analysis of variance and post hoc analysis by the Tukey-Kramer test, which allowed for multiple comparisons. The Student's unpaired t-test was used as appropriate. A value of P < 0.05 was considered statistically significant.
RESULTS
The mean baseline values for LVDP, LVEDP, HR and CF at the end of 20 min of aerobic perfusion for all hearts in Study 1 and Study 2 are shown in Supplementary Material, Table S1 . There were no significant differences between groups. C global ischaemia. In (A), hearts were randomly assigned to (i) GI, (ii) SS, (iii) SE, (iv) MS and (v) ME. In (B + C), groups SS, MS and ME were subjected to global ischaemic durations of 90 or 120 min. In Study 2, hearts were subjected to 120 min of global ischaemia (at 20 C, 28 C, 32 C or 37 C), with either 3 min of infusion of KHB or EC every 30 min. All hearts were aerobically reperfused for 60 min and recovery of myocardial function was measured. EC: esmolol cardioplegia; GI: global ischaemia alone; KHB: Krebs-Henseleit bicarbonate buffer; ME: multi-dose EC infused for 3 min every 30 min at 32 C; MS: multi-dose STH2 infused for 3 min every 30 min at 32 C; SE: single-dose EC (1.0 mmol/l) infused for 3 min at 32 C; SS: single-dose STH2 infused for 3 min at 32 C; STH2: St Thomas' Hospital cardioplegia.
(60-min ischaemia), Fig. 2C (90-min ischaemia), Fig. 2E (120-min ischaemia) and Supplementary Material, Table S1 . Hearts subjected to GI recovered slowly to a final value of 40 ± 5%; this was similar to hearts protected with a single infusion of EC (SE; 45 ± 3%). However, hearts protected with single (SS) or multiple (MS) STH2 recovered more rapidly and to a significantly higher final level (at 63 ± 6% and 66 ± 3%, respectively), whereas multiple esmolol (ME) protection induced very rapid recovery to a significantly higher value (88 ± 3%). Subsequent experiments with extended ischaemic durations of 90 min and 120 min compared only single and multiple STH2 (SS and MS) with multiple EC (ME). At both durations, LVDP recovery after protection with multiple EC was significantly higher than for STH2. Recovery of LVEDP (Fig. 2B , D and F; Supplementary Material, Table S1 ) demonstrate similar results; in groups GI, SE and SS, LVEDP increased significantly by 5 min of reperfusion but subsequently declined gradually to levels significantly higher than the baseline value. In contrast, LVEDP in MS and ME groups returned to levels that were close to baseline, mimicking the elevated LVDP recovery.
The recovery values for HR and CF at 60 min of reperfusion are shown in Supplementary Material, Table S1 . Interestingly, recovery of CF in ME hearts was significantly higher than the STH2 groups.
Ischaemic contracture. The development of left ventricular contracture during ischaemia is illustrated in Fig. 3A -C (60-min, 90-min and 120-min ischaemia, respectively). Contracture in the esmolol groups started later than other groups, and this tended to correlate with outcome, unlike peak contracture where there was no correlation.
Injury markers. CK leakage was measured in hearts undergoing 90 min and 120 min of ischaemia (Supplementary Material, Table S1 ). At 90 min, multiple STH2 and EC had significantly lower levels of CK leakage than the single STH2 group of hearts. Surprisingly, in hearts subjected to 120 min of ischaemia, multiple STH2 had a higher release of CK than single STH2 infusion and multiple EC; however, these values were not different.
Study 2: efficacy of esmolol cardioplegia on myocardial protection at various temperatures
Postischaemic recovery of function. The changes in recovery of LVDP, LVEDP, HR and CF are shown in Fig. 4 . EC significantly improved recovery of LVDP (Fig. 4A ) compared with hypothermia alone with KHB solution at all temperatures, except at 37 C where almost no recovery was observed in both conditions. After EC, there were no differences in final (60 min) recovery of LVDP at 20 C, 28 C and 32 C; recovery of LVDP at 20 C with KHB was similar to that at 32 C with EC but was significantly lower at higher temperatures. These data were mirrored by the LVEDP data (Fig. 4B) ; EC protected LVEDP such that it was only marginally higher after 20 C and 28 C. Similar levels of LVEDP were seen with EC at 32 C and KHB at 20 C, reciprocating the LVDP data. HR (Fig. 4C ) recovered to similar levels in all hypothermia groups. However, although HR recovery was delayed with EC at 37 C, it did recover to the same extent by 60 min; in contrast, there was almost no recovery with KHB after ischaemia at 37 C. Interestingly, recovery of CF in all hypothermic EC groups was almost complete (or even hyperaemic) and was C. In contrast, the onset of contracture with EC protection did not occur until 25 min at 37 C, was delayed to 80 min at 32 C and did not occur at all at 28 C and 20 C. Peak contracture was significantly higher in the KHB groups of hearts than was seen with EC.
Myocardial injury and viability. Increasing hypothermia decreased CK leakage with both KHB and EC and correlated with recovery of function (Fig. 6A) ; however, EC was also associated with significant CK reduction compared with KHB. Myocardial viability (Fig. 6B) was similar for both groups of hearts at 20 C, 28 C and at 37 C but was significantly higher with EC at 32 C.
DISCUSSION
Previously, we demonstrated that normothermic EC (1 mmol/l) (either crystalloid or blood based) during normothermic ischaemia provided equivalent or improved cardioprotection to that of STH2 in isolated rat heart studies [5] [6] [7] . We also characterized the mode of action of esmolol in isolated rat myocytes and showed that esmolol inhibits both L-type calcium channels and fast sodium channels [9] . However, earlier studies [18] showed that additional protection with the calcium channel blocker, verapamil, when used as an additive anti-ischaemic agent to STH2, declined as the temperature was reduced; hence, it was important to determine the protective efficacy of EC at hypothermia. This study demonstrated that (i) EC (1.0 mmol/l esmolol) was efficacious at hypothermia ranging from 20 C to 32 C with significantly improved protection compared with STH2 or KHB (ischaemia alone) and (ii) the infusion interval with EC could be extended to at least 30 min, thereby enhancing the clinical feasibility of using EC.
Hypothermia has been the cornerstone of myocardial protection since the first cardiac surgery operations, and it has been shown to exert an additive protective effect to cardioplegic arrest [19] . Increasing hypothermia reduces metabolism, and this will influence esmolol degradation, as has been examined in a number of studies. Melendez et al. [13] examined the effects of esmolol at 50 mg/ml (equivalent to 150 mmol/l) incubated in human whole blood at 37 C, 25 C, 15 C and 4 C and observed an increase in the half-life of esmolol from 19 min at 37 C to 47, 152 and 227 min at 25 C, 15 C and 4 C, respectively. It was suggested that the extended half-life could lead to persistent b-blockade that would either provide additional protection of the heart post-cardiopulmonary bypass (CPB) or lead to difficulty in weaning from CPB. Similarly, Jacobs et al. [12] observed temperature dependency of esmolol degradation during CPB but no difficulty in weaning from CPB. In addition, Cork et al. [10] infused esmolol during CPB in patients undergoing cardiac surgery (predominantly CABG alone); nasopharyngeal and myocardial temperatures reached during CPB were 31 C and 20 C, respectively, and esmolol concentration reached a highest value of 10.5 mg/ml (30 mmol/l) during aortic cross-clamp. Esmolol infusion improved recovery of function during the 1st hour post-CPB with no adverse clinical effects. The concentrations of esmolol used in the above studies were significantly lower than in this study; we used an esmolol concentration of 1.0 mmol/l to induce arrest, as this has previously been shown by us [5] to be the optimal dose for induction of arrest; others [20] have used a similar but slightly higher (1.7 mmol/l) induction dose for arrest.
Clinically, Sweeney and Frazier [21] were the first to successfully use esmolol (as a bolus of 10 mg/kg, followed by continuous infusion at 0.5 mg/kg/min) in patients with severely compromised left ventricular function (ejection fraction of 22%) undergoing coronary revascularization without cardioplegic arrest and CPB (LVAD support). Subsequently, experimental [20, 22] and clinical studies [11, 23, 24] have demonstrated the efficacy of esmolol in providing cardioprotection that was equivalent or superior to crystalloid or blood cardioplegia. The majority of these studies, particularly those in patients, used continuous infusion of esmolol in normothermic blood perfusion that induced 'minimal myocardial contractions' rather than arrest with esmolol.
More recently, studies have been conducted in large animals (pigs) undergoing CPB and cardiac arrest for 60 min with a blood-based esmolol cardioplegia solution comprising esmolol, adenosine and magnesium (the St Thomas' Hospital polarizing solution) at hypothermia around 12 C [25] . St Thomas' Hospital polarizing solution provided comparable myocardial protection and improved contractility versus conventional potassium-based depolarizing blood cardioplegia.
In this study, recovery of function after hypothermic global ischaemia compared cardioprotection of conventional hyperkalaemic depolarizing cardioplegia (STH2) and the polarizing esmolol cardioplegia (EC). We used esmolol at 1 mmol/l because we [5] and others [20, 26] showed that ventricular arrest was induced at around that concentration and that complete recovery was obtained after washout after a relatively brief period [9] . Initial studies examined tepid hypothermia of 32 C; multidose EC improved LVDP recovery compared with multi-dose STH2 throughout reperfusion at all ischaemic durations with more rapid recovery (Fig. 2) . Interestingly, recovery of function with multidose STH2 was similar to that in the single-dose STH2 group, although LVEDP showed significantly lower values with multidose STH2. Although, conventionally, multidose cardioplegia is considered superior to single-dose cardioplegia, especially during prolonged ischaemic durations [27] , it has been shown [28] that multidose cardioplegia infusions can have a detrimental effect. These were associated with the time course of LV contracture during ischaemia (Fig. 3) ; although cardioplegia delays the onset of contracture compared with ischaemia alone, it does not abolish it completely (as was originally thought [16] ). Interestingly, with single-or multidose STH2, contracture onset occurred at similar times; despite this, peak contracture was lower with single-dose STH2, but there was no correlation with recovery of function. Ischaemic contracture is thought to occur from 'rigor bonds' due to adenosine triphosphate depletion and calcium influx [15, 16] . EC delayed the onset of ischaemic contracture, and this was correlated with improved recovery of function, as we have also shown previously [29] . EC is thought to induce a 'polarized' arrest [9] , which would have the effect of reducing adenosine triphosphate utilization and calcium overload via inhibition of sodium and calcium channels. Hypothermia per se also plays a significant role (Fig. 5) ; during ischaemia at 37 C, similar contracture occurred with either KHB or EC infusion, whereas with increasing hypothermia EC effectively abolished contracture compared to KHB and recovery of function increased with reducing temperature.
We observed that single-dose EC had no cardioprotective effect in this experimental condition, which showed recovery equivalent to the GI-alone group, despite delayed LV contracture compared with the GI group. It has been demonstrated previously [30] that b-blockade was protective during relatively short periods of normothermic low-flow global ischaemia, whereas it was ineffective for longer periods. In this study, we were able to extend the interval between EC infusions to 30 min under hypothermic conditions to achieve effective cardioprotection, whereas we previously used 10-min or 15-min intervals under normothermic conditions [5, 6] . This study suggested that an infusion interval of 60 min was too long to protect the ischaemic myocardium at 32 C. Thus, intermittent infusion may be required for EC to achieve full myocardial protection.
Limitations
We concede that the present studies were conducted in isolated rat hearts perfused in the Langendorff mode with a crystalloid buffer solution and that this represents a non-physiological situation. It is also possible that esmolol may have adverse systemic effects that would not be revealed in our study; this would require investigation in the intact animal. Previous studies [7] [8] [9] have used esmolol clinically during relative long-term continuous infusion (albeit at lower concentrations) with no report of any systemic adverse effects. Hence, we speculate that the use of short-, multiple-and high-dose infusions are unlikely to have major systemic effects, although this would need verification. In hypothermia, it is possible to prolong the infusion interval, which would decrease the total amount of esmolol infused, although the duration of activity would also be prolonged.
Myocardial ischaemic disease is a multifactorial process; there is a spectrum of injury that affects the method of myocardial protection. Hearts used in this study were taken from normal rats, and it is likely that any protective effect of esmolol would be different in jeopardized hearts with ischaemic injury or disease.
CONCLUSION
Esmolol cardioplegia (a polarizing solution), used as a multidose infusion during hypothermia, significantly improved cardioprotection compared with the depolarizing STH2. An increased infusion interval of 30 min indicates improved clinical feasibility.
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